Global Targeted Radionuclide Therapy Supply, Demand and Key Producers, 2023-2029

Global Targeted Radionuclide Therapy Supply, Demand and Key Producers, 2023-2029

The global Targeted Radionuclide Therapy market size is expected to reach $ 3154.4 million by 2029, rising at a market growth of 16.7% CAGR during the forecast period (2023-2029).

The key drivers of the radioimmunotherapy market is its potential to deliver highly targeted and precise treatment to cancer cells, sparing healthy tissues and reducing side effects compared to traditional radiation therapies. The ability of RIT to offer personalized treatment options based on specific cancer biomarkers further enhances its appeal in the field of precision medicine. However, the radioimmunotherapy market also faces challenges. One major challenge is the high cost associated with the development and production of radiopharmaceuticals, limiting access for some patients and healthcare systems. Additionally, navigating complex regulatory pathways for approval and reimbursement of RIT products can be time-consuming and resource-intensive for pharmaceutical companies. Furthermore, there may be limited awareness and acceptance of RIT among healthcare professionals and patients, leading to slower adoption rates and market penetration. Addressing these challenges requires continued research and investment in RIT technologies to improve efficacy and cost-effectiveness. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate knowledge-sharing and streamline the regulatory process.

Therapeutic Radioligands is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

This report studies the global Targeted Radionuclide Therapy demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Targeted Radionuclide Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted Radionuclide Therapy that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Targeted Radionuclide Therapy total market, 2018-2029, (USD Million)

Global Targeted Radionuclide Therapy total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Targeted Radionuclide Therapy total market, key domestic companies and share, (USD Million)

Global Targeted Radionuclide Therapy revenue by player and market share 2018-2023, (USD Million)

Global Targeted Radionuclide Therapy total market by Type, CAGR, 2018-2029, (USD Million)

Global Targeted Radionuclide Therapy total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Targeted Radionuclide Therapy market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences and Clarity Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Targeted Radionuclide Therapy market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Targeted Radionuclide Therapy Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Targeted Radionuclide Therapy Market, Segmentation by Type
Beta-emitting
Targeted Alpha Therapy

Global Targeted Radionuclide Therapy Market, Segmentation by Application
Solid Tumor
Non Hodgkin Lymphoma

Companies Profiled:
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals

Key Questions Answered

1. How big is the global Targeted Radionuclide Therapy market?

2. What is the demand of the global Targeted Radionuclide Therapy market?

3. What is the year over year growth of the global Targeted Radionuclide Therapy market?

4. What is the total value of the global Targeted Radionuclide Therapy market?

5. Who are the major players in the global Targeted Radionuclide Therapy market?